Shares of China’s biotechnology firms plunged on Dec.15 amid concerns that the Biden administration would put an investment and export ban on more Chinese companies. The decline was led by WuXi Biologics, which crashed nearly 20 percent on Wednesday, while Sino Biopharmaceutical dropped 5 percent. The Hang Seng Healthcare Index was down 7.6 percent in late afternoon trade. The mainland index tracking the healthcare sector also slumped 3.2 percent, against a drop of 0.87 percent in the broader index. The decline came after a Tuesday report from Financial Times, citing unnamed sources, that said the Biden administration would add two dozen Chinese companies, including unnamed biotechnology firms, to a trade blacklist known as the “entity list.” Healthcare firms were already under pressure on Wednesday after Chinese biotech company BeiGene Ltd plunged on its Shanghai debut, amid worries that some Chinese firms could be ordered to delist from the U.S. stock …